Home › Compare › TRXDW vs QYLD

TRXDW vs QYLD: Dividend Comparison 2026

TRXDW yields 1333.33% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRXDW wins by $241528700.58M in total portfolio value
10 years
TRXDW
TRXDW
● Live price
1333.33%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$241528700.61M
Annual income
$210,475,860,072,406.56
Full TRXDW calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — TRXDW vs QYLD

📍 TRXDW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRXDWQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRXDW + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TRXDW pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRXDW
Annual income on $10K today (after 15% tax)
$113,333.33/yr
After 10yr DRIP, annual income (after tax)
$178,904,481,061,545.56/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, TRXDW beats the other by $178,904,481,056,735.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRXDW + QYLD for your $10,000?

TRXDW: 50%QYLD: 50%
100% QYLD50/50100% TRXDW
Portfolio after 10yr
$120764350.32M
Annual income
$105,237,930,039,032.94/yr
Blended yield
87.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on TRXDW right now

TRXDW
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Altman Z
-42.6
Piotroski
3/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRXDW buys
0
QYLD buys
0
No recent congressional trades found for TRXDW or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRXDWQYLD
Forward yield1333.33% ✓11.92%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$241528700.61M ✓$25.4K
Annual income after 10y$210,475,860,072,406.56 ✓$5,659.31
Total dividends collected$239239876.27M ✓$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: TRXDW vs QYLD ($10,000, DRIP)

YearTRXDW PortfolioTRXDW Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$144,033$133,333.33$10,352$1,192.36+$133.7K → TRXDW
2$1,948,924$1,794,807.89$10,830$1,347.57+$1.94M → TRXDW
3$24,782,219$22,696,870.86$11,460$1,539.07+$24.77M → TRXDW
4$296,245,945$269,728,970.81$12,275$1,777.84+$296.23M → TRXDW
5$3,330,378,004$3,013,394,842.54$13,323$2,078.95+$3330.36M → TRXDW
6$35,223,684,321$31,660,179,856.69$14,667$2,463.34+$35223.67M → TRXDW
7$350,636,384,108$312,947,041,885.16$16,396$2,960.57+$350636.37M → TRXDW
8$3,286,630,500,315$2,911,449,569,318.85$18,631$3,612.97+$3286630.48M → TRXDW
9$29,021,346,295,663$25,504,651,660,325.88$21,548$4,482.15+$29021346.27M → TRXDW
10$241,528,700,608,766$210,475,860,072,406.56$25,398$5,659.31+$241528700.58M → TRXDW

TRXDW vs QYLD: Complete Analysis 2026

TRXDW — Stock

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

Full TRXDW Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this TRXDW vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRXDW vs SCHDTRXDW vs JEPITRXDW vs OTRXDW vs KOTRXDW vs MAINTRXDW vs XYLDTRXDW vs JEPQTRXDW vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.